A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Bois A, du; HJ, Lück; W, Meier; HP, Adams; V, Möbus; S, Costa; T, Bauknecht; B, Richter; M, Warm; W, Schröder; S, Olbricht; U, Nitz; C, Jackisch; G, Emons; U, Wagner; W, Kuhn; J, Pfisterer

doi:10.1093/jnci/djg036

Public

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

Shared by NobleBlocks on Sep 1, 2003 • 12:00 AM UTC

Authors:

du Bois A

Lück HJ

Meier W

Abstract

Background Despite considerable improvement in the treatment of advanced ovarian cancer, the optimization of efficacy and tolerability remains an important issue. Therefore, we performed a randomized, phase III non-inferiority trial comparing paclitaxel plus cisplatin (PT) with paclitaxel plus carbo...

Discussions